BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sphingomab: Phase Ib/IIa started

Lpath began the open-label, U.S. Phase Ib/IIa PEDigree trial to evaluate 0.5 and 2 mg intravitreal iSONEP given monthly for up to 3 months in 32 patients with PED that...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >